Cleared Traditional

K862821 - CAPPEL DIAGNOSTICS ANA KIT

K862821 is an FDA 510(k) clearance for CAPPEL DIAGNOSTICS ANA KIT, manufactured by Cappel Diagnostics, Inc.. The device is a Class 2 Immunology device with product code DHN cleared through the Traditional 510(k) pathway after a 21-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1986
Decision
21d
Days
Class 2
Risk

K862821 is an FDA 510(k) clearance for the CAPPEL DIAGNOSTICS ANA KIT. Classified as Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control (product code DHN), Class II - Special Controls.

Submitted by Cappel Diagnostics, Inc. (Davis, US). The FDA issued a Cleared decision on August 15, 1986 after a review of 21 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

FDA 510(k) Submission Details - K862821

510(k) Number K862821 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 25, 1986
Decision Date August 15, 1986
Days to Decision 21 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
84d faster than avg
Panel avg: 105d · This submission: 21d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DHN Device Classification - Class 2, Special Controls

Product Code DHN Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DHN Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control

All 109
Devices cleared under the same product code (DHN) and FDA review panel - the closest regulatory comparables to K862821.
HISTONES EIA DIAGNOSTIC KIT
K870458 · Biohytech International, Inc. · Mar 1987
RAT LIVER NUCLEI TEST SYSTEM
K870732 · Val Tech Diagnostics, Inc. · Mar 1987
ANTI-DNA MICROASSAY
K863717 · Diamedix Corp. · Oct 1986
AFT-HEP SYSTEM
K860183 · Behring Diagnostics, Inc. · Feb 1986
FANA 60
K854314 · American Bio-Reagents, Inc. · Dec 1985
SS-A(RO) & SS-B(LA) ANTIBODY ASSAY
K852033 · Meloy Laboratories, Inc. · Jun 1985